Aspira Womens Health (Aspira Womens Health) ROCE %

: -712.47% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aspira Womens Health's annualized ROCE % for the quarter that ended in Dec. 2023 was -712.47%.

Aspira Womens Health ROCE % Historical Data

The historical data trend for Aspira Womens Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-167.03

-153.32

-139.16

-138.13

-290.28

Aspira Womens Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-164.37	-264.77	-435.86	-563.26	-712.47

Aspira Womens Health ROCE % Calculation

Aspira Womens Health's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-18.852	/	( ( (17.373 - 5.527)	+	(6.262 - 5.119) )	/ 2 )
	=	-18.852	/	( (11.846	+	1.143)	/ 2 )
	=	-18.852	/	6.4945
	=	-290.28 %

Aspira Womens Health's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-16.54	/	( ( (8.662 - 5.162)	+	(6.262 - 5.119) )	/ 2 )
	=	-16.54	/	( ( 3.5	+	1.143 )	/ 2 )
	=	-16.54	/	2.3215
	=	-712.47 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Aspira Womens Health (NAS:AWH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aspira Womens Health ROCE % Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (Aspira Womens Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Executives

Nicole Sandford	director	12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant	officer: General Counsel & Secretary	1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck	officer: Chief Financial Officer	529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick	director	2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh	director	1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan	officer: CSO & COO	327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk	director	6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell	director	6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan	officer: Interim Chief Financial Office	400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma	director	24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach	director	C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri	director, officer: President and CEO	63 INDIAN LEDGE RD., MONROE CT 06468